1 day Ago By ABMN Staff
Benitec Biopharma Inc. ( NASDAQ:BNTC – Get Free Report ) Director Suvretta Capital Management, L bought 900,000 shares of Benitec Biopharma stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average price of $13.
00 per share, for a total transaction of $11,700,000.00. Following the purchase, the director now directly owns 8,793,245 shares in the company, valued at $114,312,185.
This represents a 11.40 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink .
Benitec Biopharma Stock Performance NASDAQ BNTC opened at $13.43 on Monday. The stock has a market capitalization of $314.
95 million, a P/E ratio of -8.89 and a beta of 0.92.
Benitec Biopharma Inc. has a 52 week low of $4.75 and a 52 week high of $16.
90. The stock has a fifty day moving average of $12.25 and a 200-day moving average of $11.
15. Benitec Biopharma ( NASDAQ:BNTC – Get Free Report ) last announced its quarterly earnings data on Friday, February 14th. The biotechnology company reported ($0.
36) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.19.
Equities research analysts forecast that Benitec Biopharma Inc. will post -1.48 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Benitec Biopharma Analysts Set New Price Targets A number of equities analysts have commented on the stock. Guggenheim restated a “buy” rating and issued a $17.00 price target on shares of Benitec Biopharma in a research report on Tuesday, December 3rd.
Robert W. Baird began coverage on Benitec Biopharma in a research report on Friday, December 13th. They set an “outperform” rating and a $30.
00 price target on the stock. Baird R W raised Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $28.
00 target price on shares of Benitec Biopharma in a report on Monday, March 24th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Benitec Biopharma has an average rating of “Buy” and an average price target of $24.
43. View Our Latest Research Report on BNTC Benitec Biopharma Company Profile ( Get Free Report ) Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions.
It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Featured Stories Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter .
.
